Price Chart

Profile

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
URL https://www.exelixis.com
Investor Relations URL https://ir.exelixis.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release May. 09, 2024 (est.)
Last Earnings Release Feb. 06, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
URL https://www.exelixis.com
Investor Relations URL https://ir.exelixis.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release May. 09, 2024 (est.)
Last Earnings Release Feb. 06, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A